01 January 2000
High-dose anthracyclines in the treatment of advanced primitive neuroectodermal tumors in adults - a single institution experience.
Davorin Radosavljević, Svietislav Jelić, Zoran Tomasević, Suzana Matković, Ljiljana Stamatović, Zorica Nikolić-Tomasević, Ivan PopovMed Sci Monit 2000; 6(3): CR512-518 :: ID: 421316
Abstract
Primitive neuroectodermal tumors (PNET) are rare malignancies of presumedneural crest origin, most often presenting as bone or soft tissue masses in the trunk or axial skeleton,in children and young adults. Treatment of advanced PNET in adults is not clearly defined in the literature.Data concerning dose-intensive chemotherapy regimens for poor-risk patients with those tumors are sparse,due to rarity of PNET in adults, their diverse presentation, the variable treatment procedures appliedand the absence of direct comparisons. On the other hand, the role of anthracyclines in the treatmentof advanced soft tissue sarcomas is well known and substantial. Six advanced PNET patients were treatedat the Institute for Oncology and Radiology of Serbia, during last five years, with high-doses of doxorubicinor epidoxorubicin combined with cisplatin. The paper reviews each of our patients, discussing how doeschemotherapy influence the outcome in these patients, in context of the feasibility of high-doses ofanthracyclines in advanced settings. High dose anthracyclines (epidoxorubicin 150 mg/m2) in combinationwith cisplatin 120 mg/m2 induced a complete response lasting for 63+ months in a patient with desmoplasticmedulloblastoma of the cerebellum metastatic to bones and bone marrow. The same treatment but with theepidoxorubicin dose of 180 mg/m2 induced a complete response in a patient with olfactory neuroblastoma.Administration of high dose Doxorubicin (75 mg/m2) seems feasible in association with irradiation treatmentin patients with extraosseal Ewing sarcoma/PNET but the place of high dose chemotherapy within this settingremains to be determined.
Keywords: Antibiotics, Antineoplastic, Cerebellar Neoplasms, Disease-Free Survival, Epirubicin, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
08 Mar 2024 : Clinical Research
Evaluation of Foot Structure in Preschool Children Based on Body MassMed Sci Monit In Press; DOI: 10.12659/MSM.943765
15 Apr 2024 : Laboratory Research
The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in OsteoarthritisMed Sci Monit In Press; DOI: 10.12659/MSM.943738
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952